Secondary Progressive Multiple Sclerosis (SPMS) - Epidemiology Forecast to 2028

Secondary Progressive Multiple Sclerosis (SPMS) - Epidemiology Forecast to 2028

  • Pages: 50
  • Geography: Global
  • Delivery Timeline:
  • Publication: Jan, 2019
  • SKU: DIEI0208
  • Single User Price
    ()
    $3,250.00
  • Site User Price
    ()
    $6,500.00
  • Enterprise Price
    ()
    $9,750.00
Request Sample

Name*  
Email ID*  
Mobile*  
Company*  
Country*  
Zip Code*  
Address*  
Message*  
X

Request Sample Pages

Request Before Buy
Name*  
Email ID*  
Mobile*  
Company*  
Message*  
X

Inquire Before Buy

Send Friend
Name*  
Email ID*  
Mobile*  
Company*  
Message*  
X

Send to Friend

DelveInsight's "Secondary Progressive Multiple Sclerosis (SPMS) - Epidemiology Forecast, 2028” report provides a comprehensive analysis of the Secondary Progressive Multiple Sclerosis (SPMS) epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2028.
Markets Covered
• United States 
• EU5 (Germany, France, Italy, Spain, and the United Kingdom) 
• Japan
Study Period: 2016-2028
Secondary Progressive Multiple Sclerosis (SPMS) Epidemiology
The epidemiology section covers the historical, current as well as forecasted epidemiology for Secondary Progressive Multiple Sclerosis (SPMS) in 7 major markets. 
The data is collected by understanding the disease, reviewing numerous studies conducted by countries and by exploring different surveys as well as reports. The Key opinion leaders’ views are also taken into account to provide a deep understanding of the Secondary Progressive Multiple Sclerosis (SPMS) outlook. 
It also includes the explanation of changing trends of epidemiology outlining the Secondary Progressive Multiple Sclerosis (SPMS) scenario. Secondary Progressive Multiple Sclerosis (SPMS) Epidemiology
Segmentation The epidemiology section is further segmented according to the patient pool characteristics, such as age-specific, type-specific, sub-type specific, gender-specific etc., thus providing an in-depth and high-quality analysis. 
The report also covers the prevalent/Incidence cases as well as the treatable cases as per the therapies available for the Secondary Progressive Multiple Sclerosis (SPMS) thereby presenting the trends with detailed analysis, with the assumptions undertaken.
The data is presented in the form of graphs along with tables to effectively summarize the landscape. 

Report Scope
• The report covers detailed overview of Secondary Progressive Multiple Sclerosis (SPMS) explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns 
• It provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan 
• The Secondary Progressive Multiple Sclerosis (SPMS) Report assesses the disease risk and burden and highlights the unmet needs 
• It also helps to recognize the growth opportunities in the 7MM with respect to the patient population Key strengths 
• 10 Year Forecast 
• 7MM Coverage 
• Total Cases in Secondary Progressive Multiple Sclerosis (SPMS) Key assessments 
• Patient Segmentation in Secondary Progressive Multiple Sclerosis (SPMS) 
• Secondary Progressive Multiple Sclerosis (SPMS) Risk & Burden • Factors driving growth in a specific Secondary Progressive Multiple Sclerosis (SPMS) patient population

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM 
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries 
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028) 
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) 
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) 
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) 
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) 
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) 
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) 
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Key Companies
Speak to Analyst
Name*  
Email ID*  
Mobile*  
Company*  
Country*  
Zip Code*  
Specific Filed of Interest*  
X

Speak to Analyst

+1(919)321-6187

Related Reports

Contact Us

Phone

India: +91-11-45689769, +91-9650213330

Email

info@delveinsight.com

Address

New Delhi-110075, India

Address

304 S. Jones Blvd #2432, Las Vegas NV 89107

Phone

Outside India: +1(919)321-6187

Latest Tweets

Copyright © 2018 Delveinsight.